Figure 8.
Figure 8. BC133 did not cross react with CD34+CD38–HSCs. (A) Cord blood mononuclear cells were purified using Ficoll-Paque density gradient centrifugation and were immunostained with anti-human CD3, CD19, CD38, CD34, and BC133 antibodies. To exclude T cells and B cells from analysis, cells were gated on CD3– and CD19– populations. Different populations of cells (labeled 1 to 6) were assessed for their binding to BC133. (B) HSCs and progenitor cells were isolated from cord blood mononuclear cells using Miltenyi CD34 Microbeads. (C) TDCC by ATC (E:T ratio, 10) in the presence of BC133 against the purified CD34+ cells and MOLM13 AML cells was tested by using chromium release assay.

BC133 did not cross react with CD34+CD38HSCs. (A) Cord blood mononuclear cells were purified using Ficoll-Paque density gradient centrifugation and were immunostained with anti-human CD3, CD19, CD38, CD34, and BC133 antibodies. To exclude T cells and B cells from analysis, cells were gated on CD3 and CD19 populations. Different populations of cells (labeled 1 to 6) were assessed for their binding to BC133. (B) HSCs and progenitor cells were isolated from cord blood mononuclear cells using Miltenyi CD34 Microbeads. (C) TDCC by ATC (E:T ratio, 10) in the presence of BC133 against the purified CD34+ cells and MOLM13 AML cells was tested by using chromium release assay.

Close Modal

or Create an Account

Close Modal
Close Modal